Kimberly Bolin

Patent Agent
Full contact info

Passions

Fencing – formerly ranked in top 16 nationally for Vet40 Women’s Foil; when able, trains with her son (2016 US National Champion Div 2/Div 3 Men’s Foil; fences for UNC Chapel Hill 2022) at Salle Santa Cruz.

Supporter of Women’s Rowing, particularly the Cambridge University Boat Club

Experience

Vaxcyte Announces $862.5 Million Public Offering

February 5, 2024

Cooley advised Vaxcyte, a clinical-stage vaccine innovation company, on its $862.5 million follow-on public offering.

Read more

Related contacts

John McKenna
Partner, Palo Alto
Mark Weeks
Partner, Palo Alto
David D. Kim
Associate, San Francisco
Megan Ji
Associate, Seattle
Victoria Comesañas
Associate, Palo Alto
Megan Stallworth
Associate, Palo Alto
Charlie Kim
Partner, San Diego
Phil Mitchell
Partner, New York
Natasha Leskovsek
Of Counsel, Washington, DC
Wyatt Kernell
Associate, New York
Mika Reiner Mayer
Partner, Palo Alto
Kimberly Bolin
Patent Agent, Palo Alto
Eileen Marshall
Partner, Washington, DC
Mark Windfeld-Hansen
Senior Counsel, Palo Alto
Francis Wheeler
Partner, Colorado

Related Practices & Industries

Oyster Point Pharma to Be Acquired by Viatris

November 10, 2022

Cooley advised Oyster Point Pharma, a top ophthalmology-focused biopharmaceutical company, on its definitive agreement to be acquired by global healthcare company Viatris. Partners Mika Reiner Mayer, Brandon Fenn, Div Gupta and Ian Nussbaum led the Cooley team advising Oyster Point Pharma.

Read more

Related contacts

Mika Reiner Mayer
Partner, Palo Alto
Brandon W. Fenn
Partner, New York
Div Gupta
Partner, New York
Sarah Lightdale
Partner, New York
Eileen Marshall
Partner, Washington, DC
Howard Morse
Partner, Washington, DC
John Paul Oleksiuk
Partner, New York
Nyron J. Persaud
Partner, New York
John Robertson
Partner in Charge – Seattle, Seattle
Charity Williams
Partner, San Diego
Natasha Leskovsek
Of Counsel, Washington, DC
Ryan Montgomery
Special Counsel, Boston
Thomas Welk
Senior Counsel, San Diego
Nathan Baum
Associate, New York
Kimberly Bolin
Patent Agent, Palo Alto
Julia R. Brinton
Associate, Washington, DC
Cara Buchicchio
Associate, New York
Colette Ghazarian
Associate, Los Angeles Downtown
Liz Gold
Associate, New York
Amanda Griggs
Associate, New York
Edward (Teddy) Nimetz
Associate, New York

Related Practices & Industries

Myovant Sciences Acquired by Sumitovant Biopharma

November 4, 2022

Cooley has worked with Myovant Sciences since 2017 to develop and prosecute its owned and licensed patent portfolios and in intellectual property diligence leading up to Myovant’s acquisition by biopharmaceutical company, Sumitovant Biopharma. The total transaction value was $1.7 billion, with a total company value of $2.9 billion. Myovant aspires to redefine care for women and men through purpose-driven science, empowering medicines, and transformative advocacy.

"Myovant's two products, ORGOVYX® and MYFEMBREE® have substantial potential. We believe the combination of Sumitovant and Myovant will strengthen Myovant's product capabilities and help continue to deliver innovative therapies addressing unmet patient needs in prostate cancer and women's health," said Hiroshi Nomura, CEO of Sumitomo Pharma. "

Related contacts

Mika Reiner Mayer
Partner, Palo Alto
Kimberly Bolin
Patent Agent, Palo Alto

Vera Therapeutics – $86 Million Follow-On Offering

June 2, 2022

Cooley advised Vera Therapeutics on its $86 million follow-on offering of 55,742,026 shares of Class A common stock at a price to the public of $15.00 per share. Vera is a late-stage biotechnology company developing and commercializing transformative treatments for patients with serious immunological diseases. Jodie Bourdet, Brett White and Alexa Ekman led the Cooley team.

Related contacts

Jodie Bourdet
Partner, San Francisco
Brett White
Of Counsel, Palo Alto
Sam Miller
Associate, San Francisco
Mika Reiner Mayer
Partner, Palo Alto
Kimberly Bolin
Patent Agent, Palo Alto

Related Practices & Industries

Neurocrine Partners With Takeda to Address Psychiatric Disorders

June 30, 2020

Cooley advised Neurocrine Biosciences on its strategic partnership agreement with Takeda to develop and commercialize potential therapies in Takeda’s early- to mid-stage pipeline for psychiatric disorders. The partnership will enhance Neurocrine’s growing pipeline of treatments and strengthen the company’s position as a leading neuroscience-focused biopharmaceutical company.

Neurocrine will develop and commercialize all pipeline compounds included in the collaboration. Under the terms of the agreement, Neurocrine will pay Takeda $120 million in upfront cash and up to $495 million in development milestones, $1.4 billion in commercial milestones and double-digit royalties on net sales.

Read more

Related contacts

Rena Kaminsky
Special Counsel, Palo Alto
Jacqueline Grise
Partner, Washington, DC
Megan Browdie
Partner, Washington, DC
Jason Kent
Partner, New York
Carlos Ramirez
Partner, San Diego
Mika Reiner Mayer
Partner, Palo Alto
Kimberly Bolin
Patent Agent, Palo Alto
Connie Tong
Patent Agent, Palo Alto
Natasha Leskovsek
Of Counsel, Washington, DC
Stephanie Gentile
Partner, New York
Amanda Pacheco
Associate, Palo Alto

Related Practices & Industries

Memberships & affiliations

Silicon Valley Intellectual Property Law Association

Sigma Xi

Association for Women in Science

US Fencing Association